Plain-English translation of NCT06978933 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two new medications called and ABSK-043 together in patients with advanced liver cancer that has continued to grow despite previous treatment. The trial focuses on patients whose cancer has a specific biological marker called FGF19 overexpression, which may help the medications work better. Researchers want to understand whether this medication combination is safe and effective for this group of patients.
Many patients with advanced liver cancer develop resistance to existing treatments, and their disease continues to progress. This trial exists to test whether targeting a specific pathway (FGF19) with this new medication combination could offer hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive both medications at doses determined safe in earlier testing. You would take them until your disease progresses or you experience side effects that require stopping. The trial involves regular clinic visits for blood work, imaging scans, and check-ins with your medical team to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China